Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates (ADC), taking up its option to use Synaffix’s ...

Empagliflozin patent expiration in India leads to affordable treatment for diabetes, heart failure, and kidney disease.

Two years after first announcing the partnership, Boehringer Ingelheim and software firm Veeva Systems have launched ...

Salipro Biotech has signed a research and license agreement with Boehringer Ingelheim to accelerate the development of ...

Salipro Biotech AB, a Swedish biotech company specialising in the stabilisation of challenging drug targets, today announced a research and license agreement with Boehringer Ingelheim to accelerate ...

Germany’s Boehringer Ingelheim has launched the One Medicine Platform, a new system designed to streamline drug development, ...

Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed ...

Privately-held Swedish firm Salipro Biotech AB, a specialist in the stabilization of challenging drug targets, today ...

The One Medicine Platform replaces 20+ legacy platforms—unifying medicinal development processes & data sources into a ...

Cognizant (Nasdaq: CTSH) and Boehringer Ingelheim announced today the go-live of an end-to-end technology platform powered by ...

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in Research and Development, the company focuses on developing ...